2017
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials An Academic Research Consortium Initiative
Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials An Academic Research Consortium Initiative. Journal Of The American College Of Cardiology 2017, 69: 679-691. PMID: 28183511, DOI: 10.1016/j.jacc.2016.11.045.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesClinical Trials as TopicEndpoint DeterminationHumansNervous System DiseasesResearch DesignConceptsCardiovascular proceduresClinical trialsNeurological endpointsAcademic Research ConsortiumBenefit-risk assessmentAdjunctive pharmacologyNeurological complicationsNeurological outcomePreventive therapyClinical effectsNeurovascular injuryNeurological injuryNeurological riskEndpoint definitionsCardiovascular interventionsAscertainment methodsTherapyInjuryResearch ConsortiumRiskTrialsEndpointInherent risksSuch proceduresComplications
2015
Vaccination Serology Status and Cardiovascular Mortality: Insight from NHANES III and Continuous NHANES
Chothani A, Shah N, Patel NJ, Deshmukh A, Singh V, Patel N, Panaich SS, Arora S, Patel A, Savani C, Thakkar B, Bhatt P, Cohen MG, Grines C, Forrest JK, Badheka AO. Vaccination Serology Status and Cardiovascular Mortality: Insight from NHANES III and Continuous NHANES. Postgraduate Medicine 2015, 127: 561-564. PMID: 26174358, DOI: 10.1080/00325481.2015.1064300.Peer-Reviewed Original ResearchConceptsCV mortalityVaccination titersContinuous NHANESNHANES IIIProportional hazards regression modelingNutrition Examination Survey IIINon-influenza vaccinesExamination Survey IIINon-institutionalized patientsOverall health statusNHANES III dataSerology statusSeroprotective titersVaccination variablesCardiovascular eventsInfluenza vaccinationCardiovascular mortalityHazard ratioRoutine vaccinationNational HealthProtective effectHealth statusVaccinationReferent groupMortality